Andreas K. Buck researcher
Buck, Andreas K. 1970-
VIAF ID: 47599245 (Personal)
Permalink: http://viaf.org/viaf/47599245
Preferred Forms
- 100 0 _ ‡a Andreas K. Buck ‡c researcher
- 100 1 _ ‡a Buck, Andreas K. ‡d 1970-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
[¹²³I]Iodometomidate imaging in adrenocortical carcinoma | |
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner | |
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values | |
[68Ga]Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke | |
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^I&T during long-term follow-up | |
CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen | |
CXCR4-targeted theranostics in hematooncology: opportunities and challenges | |
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome | |
Expression von EGF-R, c-erb B2, TGF-alpha und p53 in der Frühphase der Karzinogenese im BOP-induzierten Pankreaskarzinom des Syrischen Goldhamsters mit vergleichender Darstellung im simultan entstandenen primären Leberkarzinom | |
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. | |
Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? | |
Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma. | |
Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. | |
Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. | |
Gene silencing by adenovirus-delivered siRNA. | |
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging | |
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy | |
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma | |
Impact of nonhybrid 99mTc-MDP-SPECT/CT image fusion in diagnostic and treatment of oromaxillofacial malignancies. | |
[Importance of FDG-PET/CT for surgery of rectal cancer]. | |
[In-patient nuclear medicine therapy in Germany from 2010 to 2012. Analysis of structured quality reports] | |
Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed imaging | |
Intraoperative 3-D imaging improves sentinel lymph node biopsy in oral cancer. | |
iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer? | |
Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas? | |
Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis? | |
Lenvatinib | |
Lenvatinib Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom | |
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients | |
Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma | |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. | |
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | |
Melanoma metastases to palatine tonsils obscured by physiological FDG uptake on PET/CT. | |
Molecular imaging of proliferation in malignant lymphoma. | |
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie | |
Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease. | |
Nuklearmedizinische Diagnostik von Lebertumoren | |
The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. | |
Pancreatic and hepatobiliary cancers | |
Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy | |
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings | |
Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer. | |
Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial | |
PET/CT for staging lung cancer: costly or cost-saving? | |
PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma | |
PET tracers in musculoskeletal disease beyond FDG. | |
Positron detection for the intraoperative localisation of cancer deposits | |
Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma | |
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. | |
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted? | |
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. | |
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy | |
Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. | |
Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy? | |
Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls | |
Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements | |
Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET/CT: initial experience with the keyhole approach | |
Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. | |
Repair of a-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with \(^ | |
Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia. | |
Small-animal PET imaging of isolated perfused rat heart. | |
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. | |
Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. | |
SPECT/CT. | |
Structured treatment interruption in patients with alveolar echinococcosis | |
Synthesis and biodistribution of 3'-fluoro-5-[(131)I]iodo-2'-deoxyuridine: a comparative study of [(131)I]FLIdU and [(18)F]FLT. | |
Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog | |
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. | |
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. | |
Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation | |
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. | |
Targeting CXCR4 with [\(^a suitable theranostic approach in pleural mesothelioma? | |
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI | |
Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI. | |
Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology | |
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience. | |
Thyroid incidentalomas with increased focal 18F-FDG uptake in 18F-FDG PET/CT of a patient with multiple primary cancers | |
Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells | |
Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? | |
Use of integrated FDG-PET/CT in sarcoidosis | |
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma | |
Volumetric and Texture Analysis of Pretherapeutic 18F-FDG PET can Predict Overall Survival in Medullary Thyroid Cancer Patients Treated with Vandetanib |